Category: Biosimilar

Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars

Sandoz, a Novartis division and the global leader in biosimilars, today announced a global partnership with Asia’s premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.

Five more biosimilar-free years for AbbVie’s Humira

Humira is the key drug for AbbVie, and one the company hopes it will be able to push into the $20 billion region per year region before competition arrives. After a financial deal was agreed with Amgen, it looks like the drug should have the immediate biosimilar threat removed from its path running up to the beginning of 2023.
read more

Biosimilar immunogenicity studies produce no surprises

MADRID (FRONTLINE MEDICAL NEWS) – Two biosimilar tumor necrosis factor inhibitor (TNFi) products are no more immunogenic than their reference biologic counterparts in patients with rheumatoid arthritis (RA), according to the results of two studies presented at the European Congress of Rheumatology. Results of one study, which involved 544 RA patients, showed 33.1% treated with […]

Sandoz secures fourth biosimilar approval in Europe with Rixathon

Sandoz, a division of Swiss firm Novartis, has announced that the European Commission has approved its biosimilar Rixathon for the same indications as its reference product rituximab.
These indications include the treatment of blood cancers such as non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia, and immunological disorders including rheumatoid arthritis, granulomatosis with polgyangitis and microscopic polyangitis.
read more